The role of kinases in human disease is well known in the drug discovery world, making them significant therapeutic intervention points. There are over 500 known kinases in the human kinome and over 150 are mutated or misregulated in various disease states. However, developing a selective kinase inhibitor can be both challenging and time consuming. There is thus an increasing demand for broad kinase compound profiling services. Read on to learn about some proven techniques used for kinase profiling.
Kinases are enzymes that transfer phosphate groups (PO43−) from ATP (adenosine triphosphate) to other specified proteins. They play an extensive role in signal transduction and regulation of complex cellular processes vital to maintaining life. They are highly regulated either by themselves, small molecules or protein-protein interactions (PPI). Their dysregulation is associated with various diseases such as cancer, osteoporosis, inflammatory diseases, diabetes and neurodegeneration, making them important drug targets.
Development of drugs targeting kinases relies on suitable bioassay techniques that can measure the addition of phosphate group to the molecule or the inhibition of this reaction by a test compound. Compounds can either be tested against a single kinase to identify a lead with high potency or profiled against a panel of kinases to establish their selectivity. Inhibition activity, binding affinity, selectivity and kinetics of compound binding are some of the parameters that need to be understood before candidate compounds can proceed to clinical stages. There are many assays and technologies available to study kinase activity, such as radioactive techniques, phospho-specific antibodies, mass spectrometry analysis, and more recently NanoBRET™.
Radioactive in vitro kinase assays using 32P-labelled ATP or 33P-labelled ATP are one of the oldest techniques used for studying protein phosphorylation. They rely on the transfer of radioactive phosphate groups from ATP to the substrate by a kinase, allowing detection of activity. Radioactive assays work well in cases where the site of phosphorylation or the kinase involved is unknown. They are labour intensive, require safe disposal of radioactive elements and are usually unsuitable for high throughput screening.
Use of phospho-specific antibodies is another common way to measure phosphorylation. Not only can these highly specific antibodies recognise the phosphorylated state of a particular protein, they can even discriminate between different phosphorylation sites. Phospho-specific antibodies can be used in different assay techniques such as Western blots, ELISA and immunofluorescence. However, finding specific antibody pairs can be challenging.
Homogeneous Time Resolved Fluorescence (HTRF) is a widely used assay technology that can be applied to a number of enzymatic activity assays, such as kinases, proteases, etc. It combines FRET (Fluorescence Resonance Energy Transfer Technology) with TR (Time-Resolved) measurement resulting in TR-FRET. In TR-FRET assays, proximity between donor and acceptor molecules results in fluorescent resonance energy transfer between them, generating a signal. There are two main formats for HTRF in these assays:
Some of the key advantages of HTRF are:
Despite its popularity, there are some inherent limitations to this approach such as quenching and auto fluorescence of library compounds or proteins.
All of the above techniques are end point assays requiring the destruction of the cells in order to obtain the phosphorylated protein to measure the response or activity.
A method to study kinase activity with more physiological relevance is to measure compound binding to a specific target kinase within intact cells. Promega’s NanoBRET Target Engagement is a first of its kind assay that enables researchers to quantitatively measure test compound binding at full-length kinase targets in live cells. This analysis can be performed in cultured cells via energy transfer between a 19-kDa luciferase (NanoLuc, Nluc)-tagged target kinase and a cell-permeable fluorescent energy transfer probe introduced into the assay. Addition of competing compounds results in a dose-dependent decrease in NanoBRET™ signal, which allows quantification of the intracellular affinity of the target kinase for the test compound.
Download a video to find out more about NanoBRET™ >
Some of the advantages of this technique are:
As all these approaches have their own pros and cons, the decision to select a particular technique will depend on the sample type, available instrumentation, desired throughput, etc. Although there is no single technology that can sufficiently satisfy all kinase drug discovery needs, a suitable assay format can be found for specific needs and targets.
Payash Bahuguna is Marketing Manager for Aurelia Bisocience.
She has a masters degree in Biotechnology and Entrepreneurship from the University of Nottingham and experience working with SMEs in the life science sector. Payash routinely writes blogs and articles for Aurelia Bioscience on both technical and non-technical subjects.
From mitochondrial networks that silently rebalance fusion and fission, to chromosomes that only reveal their fate in the minutes after division, live-cell imaging uncovers dynamics that static snapshots miss entirely. We explore three examples, including how tracking RNA therapeutic vehicles as they transit and escape endosomal compartments in real time resolves ambiguity that even super-resolution imaging of fixed cells can’t overcome.
By looking beyond the diffraction limit, we have established a method to quantitatively distinguish low-grade breast cancers that appear identical by traditional means. Ultimately, this nanoscale insight could expand access to novel HER2-targeted therapies by reliably identifying low expressing cohorts that would benefit from intervention.
Lipid nanoparticles (LNPs) are recognised as a leading delivery platform following clinical success in vaccine and therapeutic applications. Medicines Discovery Catapult (MDC) has built a preclinical platform to evaluate LNPs against two major challenges in the field. In this blog, Lead Scientist, Dr Phil Auckland, presents a case study of this workflow using intravenously administered LNPs encapsulating mRNA, which differentially target four major liver cell types.
